Table 2.
Differences between survivors and nonsurvivors within 100 days.
| Variable | Value, n (%) | p value | |
|---|---|---|---|
| Patient survived | Patient deceased | ||
| Gender (male) | 9 (81.8%) | 10 (100%) | 0.262 |
| Age | 42.0 ± 10.3 | 44.5 ± 14.8 | 0.572 |
| DM | 2 (18.2%) | 4 (40.0%) | 0.268 |
| Coinfection | |||
| CMV | 4 (36.4%%) | 3 (30.0%) | 0.562 |
| Bacteria | 5 (45.5%) | 5 (50.0%) | 0.590 |
| Leukemia relapse | 3 (27.3%) | 1 (10.0%) | 0.331 |
| GVHD | 2 (18.2%) | 6 (60.0%) | 0.063 |
| Hemoptysis | 4 (36.4%) | 9 (90.0%) | 0.017a |
| WBC | 2.4 (1.6–3.2) | 1.3 (0.1–3.3) | 0.307 |
| NE | 0.9 (0.4–1.9) | 0.7 (0.08–1.4) | 0.647 |
| CRP | 196.5 ± 92.5 | 255.7 ± 115.3 | 0.291 |
| Multilobar | 8 (72.7%) | 9 (100%) | 0.145 |
| Cavitary infiltrate | 6 (54.5%) | 4 (44.4%) | 0.500 |
| Reversed halo sign | 3 (27.3%) | 3 (33.3%) | 0.574 |
| Pleural effusion | 5 (45.5%) | 5 (55.6%) | 0.500 |
| Pneumothorax | 1 (9.1%) | 0 (0.0%) | 0.550 |
| Rhizopus | 7 (77.8%) | 5 (50.0%) | 0.220 |
| Extrapulmonary involvementb | 4 (36.4%) | 2 (20.0%) | 0.367 |
| Surgery | 2 (18.2%) | 0 (0%) | 0.262 |
a p value is statistically significant. bWhen the observation time was extended to 365 days, no extrapulmonary involvement occurred in the survival group and all patients with extrapulmonary involvement died within 1 year. CMV: cytomegalovirus; NE: neutrophils.